TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25872943
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment ('soft touch') applied to the sham group, once a week for the entire period of hospitalization.
Study: 25872943
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard medical care only, no additional treatment.
Study: 23531118
Drug: Glipizide 5
Normalized name: glipizide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 5 mg once daily (titrated to 10 mg if needed)
Study: 21377716
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluticasone furoate and oxymetazoline
Study: 12530483
Drug: Suppressive oral
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive oral acyclovir 400 mg three times daily
Study: 7705112
Drug: Clarithromycin in
Normalized name: clarithromycin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin in combination with rifampin (n = 8)
Study: 7705112
Drug: Clarithromycin in
Normalized name: clarithromycin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin in combination with other drugs (aminoglycoside, quinolone, clofazimine, isoniazid, ethambutol, pyrazinamide, minocycline)
Study: 7705112
Drug: Clarithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (30 mg/kg daily)
Study: 26049188
Drug: Rhubarb decontaminate
Normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb decontaminate group (15-20 g aqueous extract by gastric tube, enema, or peros, twice a day)
Study: 26049188
Drug: Traditional decontaminate
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional decontaminate group (glycerine enema or glycerol enema, twice a day)
Study: 22679301
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate (MTX) + sulfasalazine + hydroxychloroquine) with intramuscular glucocorticoids (GCs)
Study: 22679301
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with oral GC tapering scheme
Study: 22679301
Drug: MTX with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX with oral GCs
Study: 21385466
Drug: Holistic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holistic therapy (HT) consisting of light physical exercise sessions and a mental stress reduction program administered for two weeks.
Study: 15299181
Drug: RT with
Normalized name: NuCort with Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT with DDP (100 mg/m2 on d 2, 22, 42)
Study: 9043505
Drug: Infusion method
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion method
Study: 25293387
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril at bedtime for 12 weeks
Study: 25293387
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril in the morning for 12 weeks
Study: 17875033
Drug: Serotonergic antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic antidepressants (4-month prophylactic therapy)
Study: 15713522
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (cisplatin 50 mg/m2 days 1, 8 and vinorelbine 25 mg/m2 days 1, 8, 15, 22 for four cycles)
Study: 17950982
Drug: Glucose administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose administration (25 g)
Study: 12191837
Drug: Aspartame solution
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame solution (control)
Study: 25948287
Drug: healthy lifestyle
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: healthy lifestyle psychoeducational program + improved primary care usual treatment (ITAU)
Study: 21262099
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of mometasone furoate (MF)
Study: 20144173
Drug: Red clover-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red clover-derived isoflavone medication
Study: 17710979
Drug: Combined spinal-epidural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-epidural analgesia with intrathecal fentanyl 25 mcg
Study: 17710979
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine 0.25% 10 ml
Study: 10551072
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture supported by 2 implants with ball attachments
Study: 10551072
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture supported by 2 implants with an interconnecting bar
Study: 10551072
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture supported by 4 interconnected implants
Study: 8903117
Drug: Intrapulmonary insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapulmonary insulin (100 U ml-1 as an aerosol by oral inhalation after a 12-h fasting)
Study: 6401551
Drug: Slow sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow sodium tablets and Placebo tablets
Study: 30814418
Drug: Roasted barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro)
Study: 30814418
Drug: Roasted barley
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roasted barley extract (RBE) containing cyclo(d‐Phe‐l‐Pro) in male participants
Study: 27539539
Drug: High-fat, nondairy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat, nondairy meal 4 hours before dosing
Study: 27539539
Drug: High-fat, nondairy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat, nondairy meal 2 hours before dosing
Study: 27539539
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal containing dairy 2 hours before dosing
Study: 21697773
Drug: CNI elimination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CNI elimination (in patients with baseline CrCl > 50 mL/min)
Study: 21697773
Drug: CNI minimization
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI minimization (in patients with baseline CrCl > 50 mL/min)
Study: 20166586
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg emtricitabine
Study: 8378746
Drug: Very long-chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very long-chain n-3 fatty acids (0.65 g day-1)
Study: 3535007
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg) plus antacid
Study: 3535007
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg) plus antacid
Study: 29149437
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose [15 mg/kg (up to 750 mg)], intravenously on study days 0 and 5
Study: 29149437
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 cc normal saline), intravenously on study days 0 and 5
Study: 27098300
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait training after AbobotulinumtoxinA injection
Study: 27098300
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only AbobotulinumtoxinA injection)
Study: 21172701
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia and sedation (EMLA 5% cream, midazolam/nitrous oxide)
Study: 17907111
Drug: tesaglitazar 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesaglitazar 0.5 mg
Study: 17166340
Drug: tesaglitazar 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesaglitazar 1.0 mg
Study: 17166340
Drug: tesaglitazar 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesaglitazar 2.0 mg
Study: 17166340
Drug: tesaglitazar 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesaglitazar 3.0 mg
Study: 12589230
Drug: Glyburide/metformin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide/metformin combination therapy
Study: 10548357
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine (Tagamet HB)
Study: 10548357
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of Mylanta (initial 17.5-ml dose with additional doses as needed)
Study: 1918785
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg every 12 hours or 400 mg every 12 hours during acute phase, followed by 750 mg orally every 12 hours during convalescence phase)
Study: 1918785
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g every 24 hours during acute phase, followed by 1 g intramuscularly every 24 hours during convalescence phase)
Study: 6821904
Drug: Dopamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine and Dobutamine combination, 7.5 micrograms/kg/min each
Study: 31473167
Drug: VRC07-523LS (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS (1 mg/kg intravenous)
Study: 31473167
Drug: VRC07-523LS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS (5 mg/kg intravenous)
Study: 31473167
Drug: VRC07-523LS (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS (20 mg/kg intravenous)
Study: 31473167
Drug: VRC07-523LS (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS (40 mg/kg intravenous)
Study: 31473167
Drug: VRC07-523LS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS (5 mg/kg subcutaneous)
Study: 31473167
Drug: VRC07-523LS (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS (20 mg/kg intravenous, 3 doses at 12-week intervals)
Study: 31473167
Drug: VRC07-523LS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS (5 mg/kg subcutaneous, 3 doses at 12-week intervals)
Study: 29693495
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (n=37)
Study: 29693495
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (n=44)
Study: 26822749
Drug: Phenytoin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (4 mg/kg or 6 mg/kg per day for 3 months)
Study: 17573387
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day UDCA
Study: 17573387
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day UDCA
Study: 11322266
Drug: Didanosine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine once daily
Study: 10723507
Drug: Didanosine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine once daily in combination with other drugs
Study: 7646766
Drug: Chymotrypsin-galactose (CG)
Normalized name: Galactose
DrugBank: Galactose (DB11735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chymotrypsin-galactose (CG) treatment of sperm
Study: 7646766
Drug: Culture medium
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture medium treatment of sperm
Study: 25535650
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg once weekly (QW)
Study: 23981017
Drug: Prednisolone monotherapy
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone monotherapy (N = 32)
Study: 9426377
Drug: Pyridostigmine (PD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD, 120 mg p.o., 60 min before OGTT)
Study: 9426377
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose load (OGTT, 100 g p.o. at 0 min) alone
Study: 8715845
Drug: Oral temperatures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral temperatures
Study: 2403908
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily before breakfast
Study: 31116913
Drug: IVUS-guided drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVUS-guided drug-eluting stent (DES) implantation
Study: 31116913
Drug: Angiography-guided drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiography-guided drug-eluting stent (DES) implantation
Study: 26523919
Drug: Preladenant 2
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 2 mg twice daily
Study: 26523919
Drug: Preladenant 5
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 5 mg twice daily
Study: 26523919
Drug: Preladenant 10
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 10 mg twice daily
Study: 28490648
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg once daily (active control)
Study: 25485880
Drug: Acetaminophen, meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, meloxicam and gabapentin (AMG)
Study: 25485880
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and meloxicam
Study: 25485880
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and gabapentin
Study: 25485880
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four analgesic regimens
Study: 20825879
Drug: Balanced electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced electrolyte solution (BES)
Study: 17937086
Drug: 50 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/kg of tinzaparin sodium daily (Group A)
Study: 17937086
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin daily (Group B)
Study: 14624187
Drug: Paroxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (60 mg/d)
Study: 8610735
Drug: MRI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI with intravenous gadolinium contrast and manual mixing of the diffused contrast
Study: 31355323
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg weekly
Study: 31355323
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg weekly
Study: 31355323
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg weekly (after relapse on 0.2 g/kg)
Study: 31355323
Drug: 0.2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g/kg weekly (after dose reduction from 0.4 g/kg)
Study: 10623701
Drug: Oral fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenretinide 200 mg/d for 28 days before surgery
Study: 10623701
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills for 28 days before surgery
Study: 31690831
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus vinorelbine (lapatinib 1000 mg daily; vinorelbine 20 mg/m2 D1, D8 q3w)
Study: 31690831
Drug: Vinorelbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (30 mg/m2 D1, D8 q3w)
Study: 25088067
Drug: Extrafine BDP/FF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine BDP/FF NEXThaler(®) 100/6 μg bid
Study: 25088067
Drug: Extrafine BDP/FF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafine BDP/FF pMDI 100/6 μg bid
Study: 25088067
Drug: Non-extrafine BDP
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-extrafine BDP DPI 100 μg bid
Study: 19115650
Drug: 0.15% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% levobupivacaine (3.3 ml bolus on demand, 5 mg/hour background infusion)
Study: 19115650
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine (1 ml bolus on demand, 5 mg/hour background infusion)
Study: 16804151
Drug: Zopiclone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone (7.5 mg each night)
Study: 10903050
Drug: Cervical epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical epidural morphine
Study: 16901644
Drug: Bromocriptine (D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (D2 receptor agonist)
Study: 8375125
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amlodipine once daily
Study: 3760403
Drug: Potassium metabisulfite
Normalized name: Potassium Metabisulfite
DrugBank: Potassium metabisulfite (DB15841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium metabisulfite (K2S2O5, 1 mg/ml) skin testing
Study: 3760403
Drug: Single‐blind oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐blind oral provocative challenge tests with K2S2O5 (1, 5, 10, 25, and 50 mg)
Study: 24616448
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride 1,500 mg in beverage form
Study: 23739654
Drug: 2×‐RDA (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×‐RDA (1.6 g kg(‐1) d(‐1))
Study: 23739654
Drug: 3×‐RDA (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3×‐RDA (2.4 g kg(‐1) d(‐1))
Study: 23739654
Drug: RDA (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA (0.8 g kg(‐1) d(‐1))
Study: 18422711
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (FV) treatment, 5% sodium fluoride, applied twice per year
Study: 7867240
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg/day (increased to 100 mg/day based on response)
Study: 7867240
Drug: Diltiazem-SR 90
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem-SR 90 mg b.i.d. (increased to 180 mg b.i.d. based on response)
Study: 2766902
Drug: No enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No enteric-coated aspirin
Study: 23793
Drug: Camazepam 30
Normalized name: temazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camazepam 30 mg per day for 20 days
Study: 30442714
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg administered subcutaneously every 2 weeks
Study: 29793857
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously every 2 weeks
Study: 26573454
Drug: Quince syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quince syrup (0.6 cc/kg/day)
Study: 26573454
Drug: Omeprazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (1 cc/kg/day)
Study: 21922528
Drug: Palifermin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (low dose 240μg/kg)
Study: 21922528
Drug: Palifermin (day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palifermin (day 30 ALC >600 ×106/L)
Study: 12893983
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg sibutramine daily for 54 weeks
Study: 16494645
Drug: diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac potassium sachets (50 mg)
Study: 16494645
Drug: diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac potassium tablets (50 mg)
Study: 10784227
Drug: Quinapril 10
Normalized name: quinapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 10 mg daily for 7 days
Study: 26630717
Drug: Oral-B P35
Normalized name: Dna plasmid containing genes coding for the human interleukin 12 (il-12) p35 and p40 subunits that are separated by an internal ribosomal entry site (ires) and under the control of a single cytomegalovirus (cmv) promoter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B P35 toothbrush
Study: 2932989
Drug: Albuterol 200
Normalized name: ALBUTEROL 200MCG CAP,INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 200 micrograms
Study: 3485071
Drug: Lactate-gel (pH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate-gel (pH 3.5, 5 ml) inserted into the vagina daily for 7 days
Study: 3485071
Drug: Oral metronidazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronidazole, 500 mg twice daily for 7 days
Study: 3485071
Drug: Both lactate-gel
Normalized name: lactate / salicylic acid Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both lactate-gel and metronidazole
Study: 24675287
Drug: Tamoxifen 30mg
Normalized name: tamoxifen 30 MG
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 30mg daily for one year
Study: 22499461
Drug: Home-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intervention program supervised by home helpers, including a self-administered exercise program and 10 g amino-acid supplementation.
Study: 12047483
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg single dose on day 1 followed by 62.5 mg twice daily for 5.5 days
Study: 12047483
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg twice daily for 5.5 days plus ketoconazole 200 mg once daily for 6 days
Study: 10068176
Drug: OTFC (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTFC (various doses: 200, 400, 600, 800, 1200, 1600 microg)
Study: 10068176
Drug: Usual rescue
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual rescue drug
Study: 29566379
Drug: Apabetalone 100mg
Normalized name: Apabetalone
DrugBank: Apabetalone (DB12000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apabetalone 100mg twice-daily for 24 and 26 weeks